Keytruda Prescribing & Dosing Schedule

Dosage & Administration Drug label Prior authorization Pharmacy Financial assistance Patient education People also ask

Keytruda(pembrolizumab)

Keytruda 50 MG Injection

NO BOXED WARNING

Dosage & Administration

* Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* NSCLC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* cHL or PMBCL: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* Urothelial Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MSI-H or dMMR Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* MSI-H or dMMR CRC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Gastric Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Esophageal Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Cervical Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.
* HCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* BTC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* MCC: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* RCC: 200 mg every 3 weeks or 400 mg every 6 weeks as a single agent in the adjuvant setting, or in the advanced setting with either:
* axitinib 5 mg orally twice daily or
* lenvatinib 20 mg orally once daily.

* Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks
* in combination with carboplatin and paclitaxel regardless of MMR or MSI status, or
* in combination with lenvatinib 20 mg orally once daily for pMMR or not MSI-H tumors, or
* as a single agent for MSI-H or dMMR tumors.

* TMB-H Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.
* cSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* TNBC: 200 mg every 3 weeks or 400 mg every 6 weeks.
* Administer KEYTRUDA as an intravenous infusion over 30 minutes after dilution.
* See Full Prescribing Information for dosage modifications for adverse reactions and preparation and administration instructions.

drug label

Keytruda Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

prior authorization

Keytruda Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jun 26, 2024Arizona - Uniform Prior Authorization Form

Verified: Jun 26, 2024Colorado - Uniform Prior Authorization Form

Verified: Jun 26, 2024Hawaii - Uniform Prior Authorization Form

Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form

Verified: Jun 26, 2024Indiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Louisiana - Uniform Prior Authorization Form

Verified: Jun 26, 2024Minnesota - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Jun 26, 2024New Mexico - Uniform Prior Authorization Form

Verified: Jun 26, 2024Oregon - Uniform Prior Authorization Form

Verified: Jun 26, 2024Texas - Uniform Prior Authorization Form

Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form

Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form

Coverage Authorization Request

Coverage Authorization Appeals

Merck Access Program Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Enrollment Form (HCP Only) - 2024

Merck Access Program Electronic Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Electronic Enrollment Form (HCP Only) - 2024

Merck Access Program Enrollment Form 2024 (HCP + Patient Authorization) - Spanish

Benefits investigation

Merck Access Program Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Enrollment Form (HCP Only) - 2024

Merck Access Program Electronic Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Electronic Enrollment Form (HCP Only) - 2024

Merck Access Program Enrollment Form 2024 (HCP + Patient Authorization) - Spanish

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

pharmacy

Keytruda Preferred Pharmacy

Pharmacy List

financial assistance

Keytruda Financial Assistance Options

Copay savings program

Merck Access Program Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Enrollment Form (HCP Only) - 2024

Merck Access Program Electronic Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Electronic Enrollment Form (HCP Only) - 2024

Enroll in Patient Savings Program

Merck Access Program Enrollment Form 2024 (HCP + Patient Authorization) - Spanish

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

Merck Access Program Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Enrollment Form (HCP Only) - 2024

Merck Access Program Electronic Enrollment Form (HCP + Patient Authorization) - 2024

Merck Access Program Electronic Enrollment Form (HCP Only) - 2024

Merck Patient Assistance Program Application

Merck Access Program Enrollment Form 2024 (HCP + Patient Authorization) - Spanish

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Keytruda Patient Education

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link